Xtl Biopharmaceuticals Ltd 6-K, filed Jul 21, 2025
Xtl Biopharmaceuticals Ltd (XTLB)
About this 6-K
Xtl Biopharmaceuticals Ltd filed this 6-K on July 21, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of July, 2025
Commission File Number: 001-36000
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name into English)
26 Ben-Gurion St.
Ramat Gan, Israel, 5257346
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
RAMAT GAN, Israel - (July, 2025) XTL Biopharmaceuticals Ltd. (the “Company”) announces today the postponement of the annual and extraordinary shareholders' meeting scheduled for July 21, 2025, since legal quorum requirements as set forth in the meeting’s convening notice were not met.
The Company has announced that the deferred annual and extraordinary shareholders meeting will reconvene on July 28, 2025, at 04:00PM (Israel Standard Time).
About XTL Biopharmaceuticals Ltd. (XTL)
XTL is an IP portfolio company. The Company holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease (SLE).
XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: ir@xtlbio.com
www.xtlbio.com
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: July 21, 2025 | XTL BIOPHARMACEUTICALS LTD. | |
| By: | /s/ Noam Band | |
| Noam Band | ||
| Chief Executive Officer | ||
2